MX2009009126A - Isomeros de niacinato de inositol y usos de los mismos. - Google Patents

Isomeros de niacinato de inositol y usos de los mismos.

Info

Publication number
MX2009009126A
MX2009009126A MX2009009126A MX2009009126A MX2009009126A MX 2009009126 A MX2009009126 A MX 2009009126A MX 2009009126 A MX2009009126 A MX 2009009126A MX 2009009126 A MX2009009126 A MX 2009009126A MX 2009009126 A MX2009009126 A MX 2009009126A
Authority
MX
Mexico
Prior art keywords
inositol
niacin
esters
chiro
allo
Prior art date
Application number
MX2009009126A
Other languages
English (en)
Inventor
Curt Hendrix
Original Assignee
Concourse Health Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concourse Health Sciences Llc filed Critical Concourse Health Sciences Llc
Publication of MX2009009126A publication Critical patent/MX2009009126A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un éster que se forma a partir de un inositol o derivado de inositol y niacina, en el cual el inositol o los derivados de inositol comprenden un estereoisámero que se selecciona a partir de alo-inositol, cis-inositol, epi-inositol, muco-inositol, neo-inositol, escilo-inositol, D-quiro-inositol y L-quiro-inositol, y sales farmacéuticamente aceptables de los mismos. Los ejemplos de ésteres incluyen hexaniacinatos de inositol tales como hexaniacinato de alo-inositol y hexaniacinato de cis-inositol. Los ésteres se pueden utilizar para tratar cualquier trastorno que pueda ser tratado con terapia con niacina tales como dislipidemia, hipercolesterolemia, hiperlipidemia o enfermedad vascular. Los ésteres se pueden administrar con otros agentes tales como inhibidores de HMG CoA reductasa, estatinas, fibratos, activadores de receptores activados de proliferador de peroxisoma, policosanol, fitoesteroles, tocotrienoles, calcio, secuestrantes de ácido biliar, goma guar y niacina libre. La invención incluye composiciones farmacéuticas que contienen estos compuestos.
MX2009009126A 2007-03-01 2008-02-29 Isomeros de niacinato de inositol y usos de los mismos. MX2009009126A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89245607P 2007-03-01 2007-03-01
US96005807P 2007-09-13 2007-09-13
PCT/US2008/002735 WO2008106227A1 (en) 2007-03-01 2008-02-29 Isomers of inositol niacinate and uses thereof

Publications (1)

Publication Number Publication Date
MX2009009126A true MX2009009126A (es) 2009-10-28

Family

ID=39721559

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009126A MX2009009126A (es) 2007-03-01 2008-02-29 Isomeros de niacinato de inositol y usos de los mismos.

Country Status (10)

Country Link
US (1) US20090326013A1 (es)
EP (1) EP2114151A4 (es)
JP (1) JP2010520208A (es)
KR (1) KR20100015343A (es)
CN (1) CN101686674A (es)
AU (1) AU2008219599A1 (es)
CA (1) CA2679403A1 (es)
IL (1) IL200589A0 (es)
MX (1) MX2009009126A (es)
WO (1) WO2008106227A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5801540B2 (ja) * 2010-06-17 2015-10-28 ロート製薬株式会社 医薬組成物
EP2584899B1 (en) * 2010-06-24 2018-01-10 Trustees Of Tufts College Niacin mimetics, and use thereof
CA2802952A1 (en) * 2010-06-24 2011-12-29 Arisaph Pharmaceuticals, Inc. Niacin mimetics, and methods of use thereof
WO2014110234A1 (en) * 2013-01-09 2014-07-17 Elan Pharmaceuticals, Llc Methods of treating developmental and personality disorders
CN104799299A (zh) * 2014-01-26 2015-07-29 天津中瑞药业股份有限公司 一种含黄芪及肌醇烟酸酯食品营养强化剂制备方法
TW201618777A (zh) * 2014-09-26 2016-06-01 興和股份有限公司 脂質異常症治療劑
CN105153025A (zh) * 2015-09-23 2015-12-16 潍坊盛瑜药业有限公司 肌醇烟酸酯晶型a及其制备方法
CA3108838A1 (en) * 2018-08-22 2020-02-27 Societe Des Produits Nestle S.A. Composition comprising isomers of inositol and its use
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
KR102377167B1 (ko) 2022-01-17 2022-03-23 주식회사 지웨이코스메틱 파라고무나무 잎 추출물을 함유하는 화장료 조성물의 제조 방법
WO2023168329A2 (en) * 2022-03-02 2023-09-07 Mitopower, Inc. Novel prodrugs derived from nicotinic acid and ribose

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674836A (en) * 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en) * 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (es) * 1974-06-07 1981-03-18
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) * 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4686237A (en) * 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4801597A (en) * 1985-06-11 1989-01-31 University Of Florida Certain inositol-nicotinate ester derivatives and polyionic complexes therefore useful for treating diabetes meuitus, hyperlipidemia and lactic acidosis
US4895558A (en) * 1985-07-15 1990-01-23 University Of Queensland Autologous plasma delipidation using a continuous flow system
SE8605063D0 (sv) * 1986-11-26 1986-11-26 Matti Siren Derivatives of cyclohexane
US5110940A (en) * 1987-02-25 1992-05-05 Bristol-Myers Company Antihypercholesterolemic tetrazole compounds
US4759923A (en) * 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
US4965252A (en) * 1988-06-28 1990-10-23 Hauser-Kuhrts, Inc. Cholesterol-lowering combination compositions of guar gum and niacin
US4911917A (en) * 1988-06-28 1990-03-27 Hauser-Kuhrts, Inc. Cholesterol-lowering combination comopsitions of magnesium salt and niacin
US5023245A (en) * 1987-11-10 1991-06-11 Hauser-Kuhrts, Inc. Improved niacin formulation
US5049696A (en) * 1988-04-11 1991-09-17 Merck & Co., Inc. Antihypercholesterolemic compounds
US4866058A (en) * 1988-07-27 1989-09-12 Izydore Robert A Method for control of hyperlipidemia
IT1226726B (it) * 1988-07-29 1991-02-05 Zambon Spa Composti attivi come inibitori della biosintesi del colesterolo.
US5196440A (en) * 1988-07-29 1993-03-23 Zambon Group S.P.A. Compounds active as inhibitors of the cholesterol biosynthesis
US5011947A (en) * 1988-08-25 1991-04-30 Bristol-Myers Antihypercholesterolemic alkylene compounds
US5166364A (en) * 1989-02-27 1992-11-24 E. R. Squibb & Sons, Inc. Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5099035A (en) * 1989-02-27 1992-03-24 E. R. Squibb & Sons, Inc. Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5010105A (en) * 1989-06-09 1991-04-23 Merck & Co., Inc. Antihypercholesterolemic compounds
US4970221A (en) * 1989-07-28 1990-11-13 E. R. Squibb & Sons, Inc. 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5106992A (en) * 1989-07-28 1992-04-21 E. R. Squibb & Sons, Inc. 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5025017A (en) * 1989-09-28 1991-06-18 E. R. Squibb & Sons, Inc. Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
US5189180A (en) * 1989-09-28 1993-02-23 E. R. Squibb & Sons, Inc. Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
US5217992A (en) * 1989-10-04 1993-06-08 Bristol-Myers Squibb Company Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders
IT1237793B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
SE8904355D0 (sv) * 1989-12-21 1989-12-21 Perstorp Ab Medicament
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
US5200424A (en) * 1990-08-28 1993-04-06 Hoechst Aktiengesellschaft Use of 10-membered ring lactones as lipid regulators
US5157134A (en) * 1992-03-12 1992-10-20 E. R. Squibb & Sons, Inc. Dihydroxyheptanoic acids containing an oxabicycloheptane nucleus useful as antihypercholesterolemic agents
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) * 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6436406B1 (en) * 2000-06-15 2002-08-20 A. Glenn Braswell Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis
US6436173B1 (en) * 2000-09-18 2002-08-20 The Boc Group, Inc. Monolith adsorbents for air separation processes
AU2001295991A1 (en) * 2000-10-23 2002-05-06 Sankyo Company Limited Compositions for improving lipids in blood
US6916849B2 (en) * 2000-10-23 2005-07-12 Sankyo Company, Limited Compositions for improving lipid content in the blood
CN1240379C (zh) * 2000-11-07 2006-02-08 三共株式会社 过氧化脂质降低剂组合物
US20030166614A1 (en) * 2002-03-01 2003-09-04 Harrison Stanley F. Method for reducing cholesterol and triglycerides
KR101191675B1 (ko) * 2003-10-14 2012-10-17 혹꼬우 가가꾸 고오교오 가부시끼가이샤 실로-이노시톨의 제조방법
US20050267091A1 (en) * 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
US20070105793A1 (en) * 2005-11-04 2007-05-10 Curt Hendrix Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease

Also Published As

Publication number Publication date
US20090326013A1 (en) 2009-12-31
EP2114151A1 (en) 2009-11-11
EP2114151A4 (en) 2010-03-17
KR20100015343A (ko) 2010-02-12
JP2010520208A (ja) 2010-06-10
IL200589A0 (en) 2010-05-17
CN101686674A (zh) 2010-03-31
AU2008219599A1 (en) 2008-09-04
WO2008106227A1 (en) 2008-09-04
CA2679403A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
MX2009009126A (es) Isomeros de niacinato de inositol y usos de los mismos.
RU2022100434A (ru) Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения
AR081032A1 (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
EA201071035A1 (ru) Фармацевтические композиции модифицированного высвобождения, содержащие микофенолат, и способ их получения
BR112013023847A2 (pt) composições farmacêuticas compreendendo ésteres de sorbitano
EA201890380A1 (ru) Способы уменьшения риска развития сердечно-сосудистого события у субъекта, получающего терапию статином
CL2010001467A1 (es) Compuestos derivados de fenil-imidazol sustituido con un heteroaromatico biciclico; composicion farmaceutica que los comprende; y su uso como inhibidores de la pde10a para tratar trastornos neurodegenerativos o psiquiatricos como alzheimer, demencia alcoholica, trastorno del aprendizaje, esquizofrenia, adiccion a las drogas.
CY1122958T1 (el) Προ-φαρμακα εστερα της [3-(1-(1η-ιμιδαζολ-4-υλ)αιθυλ)-2-μεθυλφαινυλ] μεθανολης για μειωση ενδοοφθαλμικης πιεσης
AR045828A1 (es) Inhibidores de 3- hidroxi-3-metilglutaril -coenzima a reductasa
NZ589764A (en) NMDA receptor antagonists for the treatment of neuropsychiatric disorders
MX2010009570A (es) Composiciones farmaceuticas que tienen una biodisponibilidad deseable.
PT2323972E (pt) Compostos de tetraciclina substituídos com c7-flúor
WO2009147170A3 (en) Drug combinations comprising a dgat inhibitor and a ppar-agonist
WO2013066279A1 (en) Solid dosage forms comprising ezetimibe
WO2011123536A8 (en) Polycyclic tetracycline compounds
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
JP2007534699A5 (es)
MX2019005786A (es) Derivados de indazol utiles como inhibidores de diacilglicerido o-aciltransferasa 2.
MX2023007476A (es) Derivado de tetrahidroquinolina y uso medico del mismo.
WO2011139256A2 (en) Stable rosuvastatin formulations
RU2015111523A (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ
RS54591B1 (en) UNITS FOR SUPPRESSION OF PERIPHERAL DISORDER DISORDERS INDUCED BY ANTI-CARCINOGENIC MEANS
AR080023A1 (es) Formulacion de complejos que comprende aspirina revestida con una barrera que contiene aditivo hidrofobo e inhibidor de la hmg-coa reductasa
MY167897A (en) A compound separated from monascus-fermented rice, the preparation method and uses thereof
TR201820411T4 (tr) Rasetam ve karnitin içeren farmasötik bileşim ve bunun hazırlanış süreci.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal